Literature DB >> 34082602

Cell Viability Assays in Three-Dimensional Hydrogels: A Comparative Study of Accuracy.

Anthony J Dominijanni1, Mahesh Devarasetty1, Steven D Forsythe1, Konstantinos I Votanopoulos1,2, Shay Soker1,3.   

Abstract

Three-dimensional (3D) cell culture systems, such as tumor organoids and multicellular tumor spheroids, have been developed in part as a result of major advances in tissue engineering and biofabrication techniques. 3D cell culture offers great capabilities in drug development, screening, testing, and precision medicine owing to its physiological accuracy. However, since the inception of 3D systems, few methods have been reported to successfully analyze cell viability quantitatively within hydrogel constructs. In this study, we describe and compare commercially available viability assays developed for two-dimensional (2D) applications for use in 3D constructs composed of organic, synthetic, or hybrid hydrogel formulations. We utilized Promega's CellTiter-Glo®, CellTiter-Glo 3D, and CellTiter 96® MTS Assay along with Thermo Fisher's PrestoBlue™ assay to determine if these assays can be used accurately in 3D systems. Compared with direct cell viability commonly used in 2D cell culture, our results show cellular health output inaccuracies among each assay in differing hydrogel formulations. Our results should inform researchers of potential errors when using cell viability measurements in 3D cultures and conclude that microscopic imaging should be used, in combination, for validation. Impact statement Three-dimensional (3D) tissue organoids models are a valuable tool not only for studying drug toxicity but also for understanding human embryonic development, intra-tissue morphogenesis, and mechanisms of disease. In cancer organoids, such 3D models may be used for preclinical chemotherapy screening and for understanding cell death and viability mechanisms under physiologically relevant conditions. Cell viability assays are necessary for assessing the effect of biological reagents on cellular health and have been used on in vitro cell cultures for many years. With the increase of 3D systems in cellular biology research to determine therapeutic efficacy, two-dimensional assays that measure cell viability are being used outside their intended use on 3D constructs. In this study, we assess the accuracy of using various commercially available cell viability assays on different 3D hydrogel constructs to help researchers understand expected variability in their experimentation along microscopic imaging validation.

Entities:  

Keywords:  3D culture; hydrogel; organoid; viability assay

Mesh:

Substances:

Year:  2021        PMID: 34082602      PMCID: PMC8309413          DOI: 10.1089/ten.TEC.2021.0060

Source DB:  PubMed          Journal:  Tissue Eng Part C Methods        ISSN: 1937-3384            Impact factor:   3.273


  27 in total

1.  Accuracy of three techniques to determine cell viability in 3D tissues or scaffolds.

Authors:  Benjamin Gantenbein-Ritter; Esther Potier; Stephan Zeiter; Marije van der Werf; Christoph M Sprecher; Keita Ito
Journal:  Tissue Eng Part C Methods       Date:  2008-12       Impact factor: 3.056

2.  The Resazurin Reduction Assay Can Distinguish Cytotoxic from Cytostatic Compounds in Spheroid Screening Assays.

Authors:  Angelika Walzl; Christine Unger; Nina Kramer; Daniela Unterleuthner; Martin Scherzer; Markus Hengstschläger; Dagmar Schwanzer-Pfeiffer; Helmut Dolznig
Journal:  J Biomol Screen       Date:  2014-04-23

3.  Personalized Identification of Optimal HIPEC Perfusion Protocol in Patient-Derived Tumor Organoid Platform.

Authors:  Steven D Forsythe; Shyama Sasikumar; Omeed Moaven; Hemamylammal Sivakumar; Perry Shen; Edward A Levine; Shay Soker; Aleksander Skardal; Konstantinos I Votanopoulos
Journal:  Ann Surg Oncol       Date:  2020-07-06       Impact factor: 5.344

4.  Mesenchymal stem cells support growth and organization of host-liver colorectal-tumor organoids and possibly resistance to chemotherapy.

Authors:  Mahesh Devarasetty; Edina Wang; Shay Soker; Aleksander Skardal
Journal:  Biofabrication       Date:  2017-06-07       Impact factor: 9.954

5.  Use of the viability reagent PrestoBlue in comparison with alamarBlue and MTT to assess the viability of human corneal epithelial cells.

Authors:  Manlong Xu; David J McCanna; Jacob G Sivak
Journal:  J Pharmacol Toxicol Methods       Date:  2014-11-15       Impact factor: 1.950

6.  Optimization of collagen type I-hyaluronan hybrid bioink for 3D bioprinted liver microenvironments.

Authors:  Andrea Mazzocchi; Mahesh Devarasetty; Richard Huntwork; Shay Soker; Aleksander Skardal
Journal:  Biofabrication       Date:  2018-10-30       Impact factor: 9.954

Review 7.  Bioprinting for cancer research.

Authors:  Stephanie Knowlton; Sevgi Onal; Chu Hsiang Yu; Jean J Zhao; Savas Tasoglu
Journal:  Trends Biotechnol       Date:  2015-07-24       Impact factor: 19.536

Review 8.  A practical guide to hydrogels for cell culture.

Authors:  Steven R Caliari; Jason A Burdick
Journal:  Nat Methods       Date:  2016-04-28       Impact factor: 28.547

Review 9.  Applications of Bioengineered 3D Tissue and Tumor Organoids in Drug Development and Precision Medicine: Current and Future.

Authors:  Mahesh Devarasetty; Andrea R Mazzocchi; Aleksander Skardal
Journal:  BioDrugs       Date:  2018-02       Impact factor: 5.807

10.  Viability Reagent, PrestoBlue, in Comparison with Other Available Reagents, Utilized in Cytotoxicity and Antimicrobial Assays.

Authors:  Namrita Lall; Cynthia Joan Henley-Smith; Marco Nuno De Canha; Carel Basson Oosthuizen; Danielle Berrington
Journal:  Int J Microbiol       Date:  2013-04-04
View more
  2 in total

1.  Three-dimensional hydrogel culture systems support growth and determination of chemosensitivity of feline sarcoma and carcinoma cell lines.

Authors:  Jacqueline V J Cavalcanti; Kimberly A Selting; Mai T Ngo; Christine K Tran Hoang; David J Schaeffer; Timothy M Fan; Brendan A C Harley; Heidi Phillips
Journal:  Am J Vet Res       Date:  2022-05-14       Impact factor: 1.055

Review 2.  3D Tissue-Engineered Vascular Drug Screening Platforms: Promise and Considerations.

Authors:  Isra Marei; Tala Abu Samaan; Maryam Ali Al-Quradaghi; Asmaa A Farah; Shamin Hayat Mahmud; Hong Ding; Chris R Triggle
Journal:  Front Cardiovasc Med       Date:  2022-03-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.